Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
This review provides an overview to guide the development of AMPs that can potentially be used as antimicrobial drugs
"Characterisation of multiple substrate-specific (d)ITP/(d)XTPase and modelling of deaminated purine nucleotide metabolism" (PDF)
Weekly exposure (57 days/week) Weekly Exposure From the 1:1 Pre-blended Vial Daily blend dose 0.5 mg/day Weekly total blend 2.53.5 mg Weekly BPC-157 1.251.75 mg Weekly TB-500 1.251.75 mg Daily blend dose 1.0 mg/day Weekly total blend 5.07.0 mg Weekly BPC-157 2.53.5 mg Weekly TB-500 2.53.5 mg Daily blend dose 1.5 mg/day Weekly total blend 7.510.5 mg Weekly BPC-157 3.755.25 mg Weekly TB-500 3.755.25 mg Daily blend dose 2.0 mg/day Weekly total blend 10.014.0 mg Weekly BPC-157 5.07.0 mg Weekly TB-500 5.07.0 mg Use this to compare a blend schedule against the separate-vial weekly totals in the next tab
Kira Y, Nishikawa M, et al
Definitely buying again
Food and Drug Administration (FDA) for human or veterinary use
